On May 1, 2025 Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, reported the extension of its partnership with NEXT Oncology, one of the world’s largest Phase I Oncology Clinical Trial networks (Press release, Crown Bioscience, MAY 1, 2025, View Source [SID1234652437]). This strategic partnership will continue to leverage Crown Bioscience’s extensive experience in developing clinically relevant cancer organoid and patient-derived xenograft (PDX) models, together with NEXT Oncology’s global clinical network and Phase I clinical trials expertise.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Through this extended agreement, Crown Bioscience reaffirms its exclusive rights to provide services based on patient samples sourced from NEXT Oncology’s industry-leading global clinical trial network. This collaboration underscores Crown Bioscience’s commitment to providing the most clinically relevant PDX and organoid models and solutions for translational oncology research.
"We are thrilled to continue our exclusive partnership with NEXT Oncology," said John Gu, CEO of Crown Bioscience. "NEXT Oncology is globally recognized for its pioneering work in Phase I clinical oncology trials. Extending this partnership allows us to broaden our portfolio and strengthen our position as a leader in translational oncology platforms and integrated solutions. Our combined expertise and global reach will ensure rapid and scalable access to groundbreaking cancer models for our biopharma partners."
"NEXT Oncology is excited to continue our strong partnership with Crown Bioscience," said Dr. Anthony Tolcher, CEO of NEXT Oncology. "Together, we will continue to develop new and highly relevant patient models that Crown’s biopharma partners can utilize to advance their translational oncology programs. Our combined efforts continue to support both companies’ missions to help cancer patients receive the most advanced medicines possible."